Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2014
Price :
$35
*
At a glance
- Drugs Belnacasan (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 18 Sep 2014 New trial record